JAGUAR HEALTH, INC. Debt Instrument, Convertible, Conversion Ratio
JAGUAR HEALTH, INC. (JAGX) had Debt Instrument, Convertible, Conversion Ratio of 10.00% as of 2024-02-27, per its 10-K filed 2026-04-07.
Financial Statements › Notes › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionRatio1 · last filed 2026-04-07
- 2024-02-27: Debt Instrument, Convertible, Conversion Ratio 10.00%; Debt Instrument, Convertible, Conversion Ratio as first filed 40.00%.
| Period end | Debt Instrument, Convertible, Conversion Ratio | Debt Instrument, Convertible, Conversion Ratio as first filed |
|---|---|---|
| 2024-02-27 | 10.00% 10-K · filed 2026-04-07 | 40.00% 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |